Study of immune system changes during myeloma treatment
Part of Cancer clinical trials.
This study looks at how the immune system changes in patients with multiple myeloma who have had treatment that targets a protein called BCMA. It may help doctors understand why some treatments stop working and how to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with multiple myeloma
- Your disease has gotten worse during or after treatment that targets BCMA
- You have not started a new treatment for myeloma yet
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This study tests an investigational injection called WGb-0302 for people with multiple myeloma that has come back or not responded to standard treatments. The goal is to see if it is safe and helpful, possibly by targeting a protein on the cancer cells called BCMA.
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.